The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
News|Articles|September 23, 2022
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of September 23, 2022
Author(s)Sydney Jennings
Advertisement
US COVID-19 vaccination & booster dose status
US COVID-19 vaccination status according to the Centers for Disease Control and Prevention (CDC) as of September 22, 2022, at 6:00 AM, EDT:
Fully vaccinated plus 2 booster doses:
• Aged ≥50 years 35.5%
• Aged ≥65 years 42.8%
Fully vaccinated plus 1 booster dose:
• Total US population 48.7%
Fully vaccinated in key age groups:
• Total US population 67.8%
• Aged ≥5 years 71.9%
• Aged ≥65 years 92.3%
US confirmed cases of COVID-19 and deaths
Confirmed US cases of COVID-19 and related deaths according to the Johns Hopkins COVID-19 interactive map , as of September 23, 2022 at 3:23 PM, EDT.
3 states with highest number of new cases in past 28 days
• Texas 175 977
• California 174 629
• Florida 131 864
• Total US confirmed cases 96 006 005
• Total US confirmed deaths 1 056 153
Global total COVID-19 confirmed cases, deaths, vaccine doses administered:
• Cases 614 373 792
• Deaths 6 534 985 • Vaccine doses administered 12 252 626 472
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Clears 15-Minute Blood Test to Help Distinguish Bacterial From Viral Infections
2
4 FDA Decisions for Primary Care to Know from October 2026
3
Evolocumab Tied to 20% Lower Risk of Myocardial Infarction vs Ezetimibe in Real-World Study
4
The Future of HIV PrEP and One Step to Take Tomorrow
5